ES2052071T3 - Cuerpo oclusivo para administrar una sustancia fisiologicamente activa. - Google Patents

Cuerpo oclusivo para administrar una sustancia fisiologicamente activa.

Info

Publication number
ES2052071T3
ES2052071T3 ES89903777T ES89903777T ES2052071T3 ES 2052071 T3 ES2052071 T3 ES 2052071T3 ES 89903777 T ES89903777 T ES 89903777T ES 89903777 T ES89903777 T ES 89903777T ES 2052071 T3 ES2052071 T3 ES 2052071T3
Authority
ES
Spain
Prior art keywords
active substance
physiologically active
cavity
microporous membrane
membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89903777T
Other languages
English (en)
Spanish (es)
Inventor
John Mark Tucker
Mark Rupert Tucker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2052071T3 publication Critical patent/ES2052071T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES89903777T 1988-02-23 1989-02-23 Cuerpo oclusivo para administrar una sustancia fisiologicamente activa. Expired - Lifetime ES2052071T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB888804164A GB8804164D0 (en) 1988-02-23 1988-02-23 Bandage for administering physiologically active compound

Publications (1)

Publication Number Publication Date
ES2052071T3 true ES2052071T3 (es) 1994-07-01

Family

ID=10632193

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89903777T Expired - Lifetime ES2052071T3 (es) 1988-02-23 1989-02-23 Cuerpo oclusivo para administrar una sustancia fisiologicamente activa.

Country Status (11)

Country Link
US (1) US5254346A (enExample)
EP (2) EP0508979B1 (enExample)
JP (1) JP2716231B2 (enExample)
KR (1) KR970009723B1 (enExample)
AU (1) AU618085B2 (enExample)
DE (1) DE68915291T2 (enExample)
ES (1) ES2052071T3 (enExample)
GB (1) GB8804164D0 (enExample)
IN (1) IN172748B (enExample)
WO (1) WO1989007959A1 (enExample)
ZA (1) ZA891403B (enExample)

Families Citing this family (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849224A (en) * 1987-11-12 1989-07-18 Theratech Inc. Device for administering an active agent to the skin or mucosa
JPH02149514A (ja) * 1988-04-06 1990-06-08 Nitto Denko Corp 医薬部材
EP0470007B1 (en) * 1990-08-03 1995-03-15 Terumo Kabushiki Kaisha Wound-covering materials
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5240917A (en) * 1991-04-03 1993-08-31 Keimowitz Rudolph M Suppression of thromboxane levels by percutaneous administration of aspirin
US5123900A (en) * 1991-08-16 1992-06-23 Bertek, Inc. Moisture permeable double disk
CH686816A5 (de) * 1992-02-04 1996-07-15 Asulab Ag Einrichtung zur Abgabe eines Arzneimittels.
US6071896A (en) * 1992-06-16 2000-06-06 Gundersen Clinic, Ltd. Suppression of thromboxane levels by percutaneous administration of aspirin
DE4236886C2 (de) * 1992-10-31 1997-11-20 Klocke Verpackungs Service Behälter zur Aufnahme von aromatischen Substanzen
AU5596394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Transdermal delivery of ketorolac
FR2709670B1 (fr) * 1993-09-10 1995-10-20 Asulab Sa Dispositif en trois modules pour l'administration transdermique de médicaments par électrophorèse ou iontophorèse.
AU676430B2 (en) * 1994-03-07 1997-03-06 Theratech, Inc. Drug-containing adhesive composite transdermal delivery device
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
DE19517145C2 (de) * 1995-05-10 2000-02-24 Hexal Pharmaforschung Gmbh Transdermales therapeutisches System (TTS) zur Verabreichung von Testosteron
US5730721A (en) 1996-01-25 1998-03-24 Vesture Corporation Medical applicator and method
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US5800832A (en) * 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US6119036A (en) 1997-03-26 2000-09-12 The Board Of Regents Of The University Of Oklahoma Iontophoretic transdermal delivery device
US5919476A (en) * 1997-09-29 1999-07-06 Pmt Corporation Reinforced gel sheeting for scar treatment
US7011843B2 (en) 1997-10-01 2006-03-14 Lts Lohmann-Therapie Systeme Ag Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
DE19743484C1 (de) * 1997-10-01 1999-01-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
US20050048102A1 (en) * 1997-10-16 2005-03-03 Virotex Corporation Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
US6087341A (en) * 1998-02-12 2000-07-11 The Board Of Trustees Of The Leland Standford Junior University Introduction of nucleic acid into skin cells by topical application
WO1999061007A1 (de) * 1998-05-22 1999-12-02 Novosis Pharma Ag Zeitgesteuert freisetzende wirkstoffhaltige transdermalsysteme
DE19929197A1 (de) * 1999-06-25 2000-12-28 Novosis Pharma Ag Transdermalsysteme zur Abgabe von 5-HT3-Rezeptor-Antagonisten und ihre Verwendung zur antiemitischen Behandlung
DE19934523A1 (de) * 1999-07-22 2001-01-25 Novosis Pharma Ag Transdermalsysteme zur Abgabe von Muscarin-Rezeptor-Antagonisten und ihre Verwendung zur Behandlung von Spasmen der glatten Muskulatur im urologischen Bereich
US7713546B1 (en) * 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
USRE44145E1 (en) 2000-07-07 2013-04-09 A.V. Topchiev Institute Of Petrochemical Synthesis Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
US8449908B2 (en) * 2000-12-22 2013-05-28 Alltranz, Llc Transdermal delivery of cannabidiol
US20050113510A1 (en) 2001-05-01 2005-05-26 Feldstein Mikhail M. Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
US20050215727A1 (en) 2001-05-01 2005-09-29 Corium Water-absorbent adhesive compositions and associated methods of manufacture and use
RU2276998C2 (ru) 2001-05-01 2006-05-27 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Гидрогелевые композиции
US8541021B2 (en) 2001-05-01 2013-09-24 A.V. Topchiev Institute Of Petrochemical Synthesis Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8840918B2 (en) 2001-05-01 2014-09-23 A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences Hydrogel compositions for tooth whitening
US8206738B2 (en) 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
CA2447302C (en) 2001-05-01 2008-07-29 A.V. Topchiev Institute Of Petrochemical Synthesis Two-phase, water-absorbent bioadhesive composition
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2492654A1 (en) * 2002-07-16 2004-01-22 University Of South Florida Human immunosuppressive protein
SI1534286T1 (sl) 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
CA2506615A1 (en) 2002-11-18 2004-06-03 Yaupon Therapeutics, Inc. Analgesic uses of norketamine and ketamine/norketamine prodrugs
CA2453013C (en) * 2002-12-13 2011-02-15 Gary W. Cleary Dermal, transdermal, mucosal or transmucosal ingredient delivery devices
WO2004094457A2 (en) * 2003-04-16 2004-11-04 Arizona Board Of Regents, Acting For And On Behalf Of, Arizona State University Stable rgd peptidomimetic composition
EP1620112A4 (en) * 2003-04-17 2007-04-25 Univ Columbia DESMOGLEIN 4 IS A NEW GENUS INVOLVED IN HAIR GROWTH
WO2005007020A2 (en) 2003-07-03 2005-01-27 Corium International, Inc. Wound dressing, ingredient delivery device and iv hold-down, and method relating to same
EP1663242B1 (en) 2003-08-07 2011-04-27 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
ES2321721T3 (es) * 2003-09-08 2009-06-10 Mcneil Ab Formulaciones de nicotina y uso de las mismas.
EP1713450B1 (en) 2004-01-30 2021-10-06 Corium, Inc. Rapidly dissolving film for delivery of an active agent
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
WO2005105157A2 (en) * 2004-04-23 2005-11-10 The Trustees Of Columbia University In The City Ofnew York INHIBITION OF HAIRLESS PROTEIN mRNA
US20050249791A1 (en) * 2004-05-07 2005-11-10 3M Innovative Properties Company Antimicrobial articles
GB2414461B (en) * 2004-05-24 2007-09-12 Mark Rupert Tucker Form-fill-seal process
CN101039706A (zh) 2004-08-05 2007-09-19 考里安国际公司 粘合剂组合物
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US20060079513A1 (en) * 2004-10-13 2006-04-13 Preston David M Methods and compositions including methscopolamine nitrate
US20060079514A1 (en) * 2004-10-13 2006-04-13 Victory Pharma Incorporated Methods and compositions including methscopolamine bromide
ATE471146T1 (de) 2004-10-21 2010-07-15 Durect Corp Transdermale verabreichungssysteme
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
GB2421431B (en) * 2004-12-24 2007-10-10 Aquasol Ltd Dosing systems
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
US20090246264A1 (en) * 2005-12-08 2009-10-01 Fertin Pharma Transdermal Tobacco Alkaloid Patch
WO2007065428A1 (en) * 2005-12-08 2007-06-14 Fertin Pharma Low flexural strength transdermal tobacco alkaloid patch
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
EP2007877B1 (en) * 2006-02-28 2013-04-17 The Trustees of Columbia University in the City of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
AU2007275581B2 (en) 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
ATE497496T1 (de) 2006-10-19 2011-02-15 Rigel Pharmaceuticals Inc 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
ES2380551T3 (es) 2006-11-21 2012-05-16 Rigel Pharmaceuticals, Inc. Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
AU2007353989A1 (en) * 2007-05-31 2008-12-04 Fertin Pharma A/S Transdermal tobacco alkaloid reservoir patch
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
ES2534900T3 (es) 2007-07-30 2015-04-30 Zynerba Pharmaceuticals, Inc. Profármacos de cannabidiol, composiciones que comprenden los profármacos de cannabidiol y métodos de uso de los mismos
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090247619A1 (en) * 2008-03-06 2009-10-01 University Of Kentucky Cannabinoid-Containing Compositions and Methods for Their Use
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US8236838B2 (en) * 2008-04-21 2012-08-07 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131958A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2010033626A1 (en) * 2008-09-19 2010-03-25 Institute For Oneworld Health Compounds, compositions and methods comprising imidazole and triazole derivatives
BRPI0916920A2 (pt) * 2008-08-22 2015-11-24 Sanofi Aventis 4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metóxi-etil)-4-trifluorometóxi-1h-indol-3-il]-metanona como inibidor de triptase de mastócito, seu uso e método de preparação, bem como forma cristalina
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
JP5815411B2 (ja) 2008-12-30 2015-11-17 ライジェル ファーマシューティカルズ， インコーポレイテッド ピリミジンジアミンキナーゼ阻害剤
AU2010204986B2 (en) 2009-01-14 2016-06-02 Corium International, Inc. Transdermal administration of tamsulosin
PL2389372T3 (pl) 2009-01-23 2016-02-29 Rigel Pharmaceuticals Inc Kompozycje i sposoby hamowania szlaku JAK
EP3620154A1 (en) 2009-02-06 2020-03-11 University Of Southern California Therapeutic compositions comprising monoterpenes
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
SG176983A1 (en) 2009-07-08 2012-02-28 Dermira Canada Inc Tofa analogs useful in treating dermatological disorders or conditions
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
WO2011022371A2 (en) * 2009-08-17 2011-02-24 Silipos Inc. Gel product
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
WO2011053468A1 (en) 2009-10-30 2011-05-05 Sanofi-Aventis Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
RU2012131146A (ru) 2009-12-23 2014-02-10 Санофи Пролекарства [4[4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролпиридинил)метанонов и их синтез
CN102770431A (zh) 2009-12-23 2012-11-07 赛诺菲 [4[4-(5-氨基甲基-2-氟-苯基)-哌啶-1-基]-(1h-吡咯并吡啶-基)-甲酮及其合成
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN103068390A (zh) 2010-04-20 2013-04-24 寰宇一家健康研究所 包含哒嗪磺酰胺衍生物的化合物、组合物和方法
EP2560643A1 (en) 2010-04-20 2013-02-27 Institute for OneWorld Health Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives
AU2011242562B2 (en) 2010-04-24 2016-10-13 Mycovia Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
KR101937495B1 (ko) 2010-07-28 2019-01-10 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
CA2816088A1 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
SI2635299T1 (sl) 2010-11-02 2020-02-28 The Trustees Of Columbia University In The City Of New York Postopki za zdravljenje motenj izgube las
KR20180039185A (ko) 2010-11-13 2018-04-17 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
EA201390876A1 (ru) 2010-12-13 2013-12-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
US9320690B2 (en) 2010-12-20 2016-04-26 Colgate-Palmolive Company Gelatin encapsulated oral care composition containing hydrophilic active, hydrophobic structuring agent and oil carrier
CA2828360A1 (en) 2011-02-25 2012-08-30 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Chrysophaentin analogs that inhibit ftsz protein
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
US8809378B2 (en) 2011-06-19 2014-08-19 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN105884743B (zh) 2011-06-19 2019-08-06 威尔金制药(Nc)有限公司 金属酶抑制剂化合物
EA201490052A1 (ru) 2011-06-23 2014-04-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
BR112014005104A2 (pt) 2011-09-02 2017-07-04 Salk Inst For Biological Studi inibidores camkii, ip3r, calcineurin, p38 e mk2/3 para tratar atar distúrbios metabólicos de obesidade
EP3351541A1 (en) 2011-12-11 2018-07-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
EA026209B1 (ru) 2012-01-20 2017-03-31 Ваймет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
NZ629898A (en) 2012-03-23 2016-04-29 Oxigene Inc Compositions and methods for inhibition of cathepsins
ES2694681T3 (es) 2012-03-29 2018-12-26 The Trustees Of Columbia University In The City Of New York Métodos para tratar trastornos de pérdida capilar
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
JP2016506930A (ja) 2013-01-25 2016-03-07 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性腸疾患を処置するための化合物および方法
EP2968551B1 (en) 2013-03-15 2021-05-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
US20150157509A1 (en) * 2013-12-11 2015-06-11 Oscar Polk Atkinson Occlusive skin covering
US20150174386A1 (en) * 2013-12-19 2015-06-25 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
CA2941357A1 (en) 2014-03-07 2015-09-11 The Arizona Board Of Regents On Behalf Of The University Of Arizona Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
EP3119746A4 (en) 2014-03-19 2017-08-16 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3237452A4 (en) 2014-12-23 2018-12-05 The Trustees of Columbia University in the City of New York Fusion proteins and methods thereof
PL3271347T3 (pl) 2015-03-19 2022-11-21 Mycovia Pharmaceuticals, Inc. Związki przeciwgrzybicze i sposoby wytwarzania
ES2811136T3 (es) 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
EP3349753A4 (en) 2015-09-18 2019-01-23 VPS-3, Inc. FUNGICIDE COMPOUNDS AND METHOD OF PREPARING THEREOF
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
WO2017117393A1 (en) 2015-12-30 2017-07-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
US11622929B2 (en) 2016-03-08 2023-04-11 Living Proof, Inc. Long lasting cosmetic compositions
JP7602217B2 (ja) 2016-06-03 2024-12-18 バイオビンク エルエルシー ビスホスホネート・キノロン複合体及びそれらの用途
EP3475263B1 (en) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
WO2018002888A1 (en) 2016-06-29 2018-01-04 Halo Life Science, Llc Methods of making low odor choline salts of an organic compound
ES2939232T3 (es) 2016-10-26 2023-04-20 Rigel Pharmaceuticals Inc Derivados de oxazol para uso como inhibidores de IRAK y método para su preparación
ES2946001T3 (es) 2016-10-26 2023-07-11 Rigel Pharmaceuticals Inc Compuestos de pirazol amida como inhibidores de IRAK
EP3562487B1 (en) 2016-12-29 2023-11-29 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
GB201708579D0 (en) * 2017-05-30 2017-07-12 Univ Of Wolverhampton Science Park Ltd Wound dressing
CN111032642B (zh) 2017-06-29 2023-07-18 里格尔药品股份有限公司 激酶抑制剂及制造和使用方法
GB2561262B (en) * 2017-07-13 2019-03-20 Dentmed Ltd A targeted drug delivery pad
EP3681920B1 (en) 2017-09-13 2025-06-25 Living Proof, Inc. Long lasting cosmetic compositions
EP3681921A2 (en) 2017-09-13 2020-07-22 Living Proof, Inc. Color protectant compositions
AU2018370210B2 (en) 2017-11-20 2024-09-26 Living Proof, Inc. Properties for achieving long-lasting cosmetic performance
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
EP3784711A1 (en) 2018-04-27 2021-03-03 Living Proof, Inc. Long lasting cosmetic compositions
KR102823195B1 (ko) 2018-05-03 2025-06-20 리겔 파마슈티칼스, 인크. Rip1 억제 화합물 및 이를 제조하고 사용하는 방법
PT3788044T (pt) 2018-05-03 2023-08-31 Rigel Pharmaceuticals Inc Compostos inibidores de rip1 e métodos para preparar e usar os mesmos
JP7501960B2 (ja) 2018-07-09 2024-06-18 バイオビンク エルエルシー ビスホスホネート・キノロン複合体及びそれらの用途
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
CN114269383A (zh) 2019-01-08 2022-04-01 菲斯生物制药公司 金属酶抑制剂化合物
US11090346B2 (en) 2019-05-28 2021-08-17 Inbold Inc. Cannabinoid composition and method of sublingual, buccal and oral mucosa delivery
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
BR112022001418A2 (pt) 2019-08-08 2022-06-07 Rigel Pharmaceuticals Inc Compostos e método para tratar a síndrome de liberação de citocinas
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
PH12022550466A1 (en) 2019-08-30 2023-03-06 Rigel Pharmaceuticals Inc Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
CR20220075A (es) 2019-09-06 2022-07-14 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos
EP4025574B1 (en) 2019-09-06 2025-05-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
CN115298184B (zh) 2019-11-07 2025-01-28 里格尔药品股份有限公司 杂环rip1抑制化合物
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
WO2023136749A1 (ru) * 2022-01-11 2023-07-20 Павел Владимирович КОРЧАГИН Система и способ обеспечения безопасности для держателей банковских карт
US12384775B2 (en) 2022-03-23 2025-08-12 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
AU1147476A (en) * 1975-03-19 1977-09-01 Procter & Gamble Controlled release article
US4725272A (en) * 1981-06-29 1988-02-16 Alza Corporation Novel bandage for administering beneficial drug
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
US4752478A (en) * 1984-12-17 1988-06-21 Merck & Co., Inc. Transdermal system for timolol
EP0186019B1 (de) * 1984-12-22 1993-10-06 Schwarz Pharma Ag Wirkstoffpflaster
US4597961A (en) * 1985-01-23 1986-07-01 Etscorn Frank T Transcutaneous application of nicotine
US4756710A (en) * 1985-04-05 1988-07-12 Merck & Co., Inc. pH-Mediated drug delivery system
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
GB8512358D0 (en) * 1985-05-16 1985-06-19 Euro Celtique Sa Transdermal delivery system

Also Published As

Publication number Publication date
DE68915291T2 (de) 1994-09-01
US5254346A (en) 1993-10-19
KR970009723B1 (ko) 1997-06-17
AU618085B2 (en) 1991-12-12
KR900700153A (ko) 1990-08-11
AU3289589A (en) 1989-09-22
EP0508979B1 (en) 1994-05-11
DE68915291D1 (de) 1994-06-16
EP0508979A1 (en) 1992-10-21
GB8804164D0 (en) 1988-03-23
EP0336543A1 (en) 1989-10-11
ZA891403B (en) 1989-11-29
JP2716231B2 (ja) 1998-02-18
WO1989007959A1 (en) 1989-09-08
JPH03503636A (ja) 1991-08-15
IN172748B (enExample) 1993-11-20

Similar Documents

Publication Publication Date Title
US3598122A (en) Bandage for administering drugs
DE69102140D1 (de) Wirkstoffabgabevorrichtung die ein hydrophobisches mittel enthält.
KR900700153A (ko) 생리학적 활성물질 투여를 위한 폐색체
BE905933A (fr) Emplatres transdermiques et dermiques comportant plusieurs subdivisions.
ES2042700T3 (es) Composiciones farmaceuticas con liberacion controlada, y metodo para su preparacion.
DE3265043D1 (en) Applicators for pharmaceutically active agents, their preparation and use
DE3770550D1 (de) Tragbare osmotische einrichtung zur infusion mit geregelter freigabe.
ES2018270B3 (es) Dispositivo de liberacion controlado para una sustancia activa.
ES2052947T3 (es) Nueva forma unitaria, solida y porosa que comprende microparticulas y/o nanoparticulas asi como su preparacion.
DK156289A (da) Farmaceutisk praeparat indrettet til kontrolleret afgivelse af aktiv bestanddel
ATE248004T1 (de) Schnittstelle für iontophorese
KR950007808A (ko) 약물투여용 의료용구
KR890701164A (ko) 피부침투성 치료 시스템
ES8801123A1 (es) Procedimiento para producir un comprimido de dispensacion de un principio biologicamente activo.
ES2055677T1 (es) Procedimiento de obtencion de una composicion para el tratamiento de la disfuncion erectil.
SE7714066L (sv) Tillforselenhet for biologiskt aktiva emnen
ES2002840A6 (es) Un dispositivo para distribuir sustancias volatiles
DE69322286D1 (de) Verabreichungsvorrichtungen mit gestützten flüssigen membranen
ES2167611T3 (es) Formulaciones de gel que contienen factores de crecimiento.
BR8404607A (pt) Dispositivo para a liberacao controlada de um material ativo em um meio aquoso e pilula,pastilha,granulo,implante ou bolo alimentar de ruminantes
KR940701286A (ko) 재생성 신경계 삽입장치 및 그것을 사용하는 방법
IE882898L (en) Solubility modulated drug delivery device
DK324687A (da) Transdermalt farmeceutisk praeparat
ES8305583A1 (es) Un procedimiento para la produccion de un dispositivo para la administracion controlada y continua de un producto quimi-co particularmente farmacos, a un entorno que contiene un liquido acuoso.
ES2058627T3 (es) Sistema terapeutico para la administracion retardada y dirigida a traves de la piel o de las mucosas de sustancias activas.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 508979

Country of ref document: ES